✦ LIBER ✦

Taxol (T), Ifosfamide (I) and Carboplatin (C) is an active combination for stage IIIB–IV Non Small Cell Lung Cancer (NSCLC). A multicenter validation study

✍ Scribed by Zaniboni, A; De Marinis, F; Ardizzoni, A; Portalone, L; Boni, C; Meriggi, F; Di Molfetta, M; Floriani, I; Cafferata, M.A

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

52 Milti-institutional phase II trial of

✍ Belani, C.P.; Einzig, A.; Bonomi, P.; Dobbs, T.; Kozak, C.; Cohen, L.; Capozzoli 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 147 KB

9066 Antitumour activity of pemetrexed (

✍ Gervais, R.; Robinet, G.; Clement-Duchene, C.; Denis, F.; ElKoury, C.; Martin, P 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB

P-563 Splitted dose carboplatin (CARBO)

✍ Reck, M.; Nagel, S.; Goetz, S.; Reichardt, H.; Fischer v. Weikersthal, L.; Schne 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Carboplatin and paclitaxol (Taxol) as an

✍ M.E.R O'Brien; T Splinter; E.F Smit; B Biesma; M Krzakowski; V.C.G Tjan-Heijnen; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 161 KB